The relationship between methylation of tumor suppressor genes APC, GSTP1, RASSF1A and content of prostate-specific antigen- associated markers in prostate cancer diagnosis
https://doi.org/10.18699/SSMJ20230518
Abstract
Despite the improvement of prostate cancer (PCa) diagnostic methods and the introduction of prostate-specific antigen (PSA) monitoring, the incidence of advanced PCa in Russia remains high. New more informative variables are needed for the effective diagnosis of early stage and high-grade PCa. In the field of epigenetics of special interest is the detection of DNA hypermethylation, which can serve as a PCa biomarker, since it is common to find and may induce a stable appropriate gene silencing, leading to significant cell changes. Aim of the study was to analyze the relationship between methylation of the APC, GSTP1 and RASSF1A genes and total PSA and prostate health index (PHI) in PCa. Material and methods. The present study included 54 patients with suspicion of PCa, up to 75-years old, who had an initial total PSA level from 2.5 to 10 ng/ml. To calculate PHI value the concentrations of total PSA, free PSA and pre-mature form of PSA ([–2]proPSA) in blood serum were measured by chemiluminescence immunoassay. Results and discussion. The study has revealed the statistically significant correlation between the degree of methylation in blood plasma samples and biopsy material of only the GSTP1 gene and PSA-associated markers. We found an increase of parameters contingency as Gleason score increased. Conclusions. As a result of this work, statistically significant direct correlations were identified between changes in methylation patterns of the promoter region of the GSTP1 gene and PHI, which allows us to consider them as potential candidates for inclusion in a diagnostic panel for more effective early detection of prostate cancer.
About the Authors
I. A. Aboyan
Clinical Diagnostic Center “Zdorovie” in Rostov-on-Don
Russian Federation
Russian Federation
doctor of medical sciences, professor
344011, Rostov-on-Don, Dolomanovsky lane, 70/3
E. N. Fedotova
Clinical Diagnostic Center “Zdorovie” in Rostov-on-Don
Russian Federation
Russian Federation
344011, Rostov-on-Don, Dolomanovsky lane, 70/3
A. Yu. Maksimov
National Medical Research Centre for Oncology of Minzdrav of Russia
Russian Federation
Russian Federation
doctor of medical sciences, professor
344037, Rostov-on-Don, 14th line st., 63
E. F. Кomarova
National Medical Research Centre for Oncology of Minzdrav of Russia
Russian Federation
Russian Federation
doctor of biological sciences, professor of RAS
344037, Rostov-on-Don, 14th line st., 63
S. N. Vlasov
National Medical Research Centre for Oncology of Minzdrav of Russia
Russian Federation
Russian Federation
344037, Rostov-on-Don, 14th line st., 63
References
1. Tolkach Y., Kristiansen G. The heterogeneity of prostate cancer: a practical approach. Pathobiology. 2018;85(1-2):108−116. doi: 10.1159/000477852
2. Prensner J.R., Rubin M.A., Wei J.T., Chinnaiyan A.M. Beyond PSA: the next generation of prostate cancer biomarkers. Sci. Transl. Med. 2012;4(127):127rv3. doi: 10.1126/scitranslmed.3003180
3. Мassie C.E., Mills I.G., Lynch A.G. The importance of DNA methylation in prostate cancer development. J. Steroid. Biochem. Mol. Biol. 2017;166:1−15. doi: 10.1016/j.jsbmb.2016.04.009
4. Magrupov B.A., Inoyatov U.N. Morphological characteristics of prostate cancer and its assessment using Gleason scale. Vestnik ekstrennoy meditsiny = Emergency Medicine Bulletin. 2020;13(4):50−57. [In Russian].
5. Couñago F., López-Campos F., Díaz-Gavela A.A., Almagro E., Fenández-Pascual E., Henríquez I., Lozano R., Linares Espinós E., Gómez-Iturriaga A., de Velasco G., … Del Cerro E. Clinical applications of molecular biomarkers in prostate cancer. Cancers (Basel). 2020;12(6):1550. doi: 10.3390/cancers12061550
6. Eggener S.E., Rumble R.B., Armstrong A.J., Morgan T.M., Crispino T., Cornford P., van der Kwast T., Grignon D.J., Rai A.J., Agarwal N., Klein E.A., Den R.B., Beltran H. Molecular biomarkers in localized prostate cancer: ASCO guideline. J. Clin. Oncol. 2020;38(13):1474−1494. doi: 10.1200/JCO.19.02768
7. Sedakov I.E., Semikoz N.G., Motriy A.V., Anishchenko A.A., Maslova O.N., Basheyev A.V., Kolycheva O.V. Molecular genetic markers in the prediction and treatment of prostate cancer. Novoobrazovanie = Neoplasm. 2020;12(4):158−167. [In Russian]. doi: 10.26435/neoplasm.v12i4.349
8. Vlajnic T., Bubendorf L. Molecular pathology of prostate cancer: a practical approach. Pathology. 2021;53(1):36−43. doi: 10.1016/j.pathol.2020.10.003
9. Wu A., Cremaschi P., Wetterskog D., Conteduca V., Franceschini G.M., Kleftogiannis D., Jayaram A., Sandhu S., Wong S.Q., Benelli M., … Attard G. Genome-wide plasma DNA methylation features of metastatic prostate cancer. J. Clin. Invest. 2020;30(4): 1991−2000. doi: 10.1172/JCI130887
10. Rakul S.A., Kamilova T.A., Golota A.S., Shcherbak S.G. Prognostic and predictive biomarkers of prostate cancer. Onkourologiya = Oncourology. 2017;13(4):111−121. [In Russian]. doi: 10.17650/17269776-2017-13-4-111-121
11. Rapoport L.M., Bezrukov E.A., Sukhanov R.B., Krupinov G.E., Tsarichenko D.G., Martirosyan G.A., Avakyan S.K. Biomarkers for diagnosing of prostate cancer: the present and the future. Andrologiya i genital’naya khirurgiya = Andrology and Genital Surgery. 2018;19(1):68−76. [In Russian]. doi: 10.17650/2070-9781-2018-19-1-68-76
12. Silin A., Martinkov V., Nadyrov E., Pestrikov E., Liburkin O., Zadorozhnyuk A., Tropashko I., Silina A., Martynenko S., Voropayeva A. Comparative analysis of methylation status of suppressor genes in the prostate gland tissue in patients with benign pathology, prostate cancer and in patients without pathology. Problemy zdorov’ya i ekologii = Health and Environment Issues. 2012;(4):92−98. [In Russian].
13. Aboyan I.A., Fedotova E.N., Maksimov A.Yu., Komarova E.F. Effectiveness of evaluation of APC, GSTP1 and RASSF1A methylation level as a prostate cancer marker. Ul’yanovskiy mediko-biologicheskiy zhurnal = Ulyanovsk Biomedical Journal. 2022;(3):7385. doi: 10.3401-4/2227-1848-2022-3-73-85
14. Maruyama R., Toyooka S., Toyooka K.O., Virmani A.K., Zöchbauer-Müller S., Farinas A.J., Minna J.D., McConnell J., Frenkel E.P., Gazdar A.F. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin. Cancer. Res. 2002;8(2):514−519.
15. Ren G., Li G. Tumor suppressor gene DLC1: Its modifications, interactive molecules, and potential prospects for clinical cancer application. Int. J. Biol. Macromol. 2021;182:264−275. doi: 10.1016/j.ijbiomac.2021.04.022
16. Chen S., Duan H., Zhang D., Sun G. Correlation between RASSF1A methylation in cell-free dna and the prognosis of cancer patients: a systematic review and meta-analysis. J. Oncol. 2022;2022:3458420. doi: 10.1155/2022/3458420
17. Zhou X., Jiao D., Dou M., Chen J., Li Z., Li Y., Liu J., Han X. Association of glutathione-S-transferase p1 gene promoter methylation and the incidence of prostate cancer: a systematic review and meta-analysis. J. Cancer. Res. Clin. Oncol. 2019;145(8):1939−1948. doi: 10.1007/s00432-019-02962-8
Review
For citations:
Aboyan I.A., Fedotova E.N., Maksimov A.Yu., Кomarova E.F., Vlasov S.N. The relationship between methylation of tumor suppressor genes APC, GSTP1, RASSF1A and content of prostate-specific antigen- associated markers in prostate cancer diagnosis. Сибирский научный медицинский журнал. 2023;43(5):163-168. (In Russ.) https://doi.org/10.18699/SSMJ20230518
Views:
305
Email this article 